|
Home
>
Disciplines
>
Medicine
>
Oncology
>
Prostate
cancer
>
Prognosis
>
Risk
classification
>
Overview
|
|
|
CONTENTS
|
|
|
INITIAL
PRESENTATION
■
PREDIAGNOSTIC
RISK ASSESSMENT WITH PROSTATE MRI AND MRI-TARGETED
BIOPSY
INSIGNIFICANT
DISEASE
PSA
VELOCITY AND CLASSIFICATION
RISK
FACTORS: IMPACT DEPENDS ON RISK GROUP
■
POSITIVE
SURGICAL MARGINS
RISK
GROUPS BY PERCENT OF POSITIVE CORES
COMPARISON
OF PRETREATMENT RISK STRATIFICATION TOOLS
|
|
|
INITIAL
PRESENTATION
|
|
|
|
.
|
Herlemann A, Washington SL 3rd, Eapen RS, Cooperberg MR.
Whom
to Treat: Postdiagnostic Risk Assessment with Gleason Score, Risk
Models, and Genomic Classifier.
Urol Clin North Am. 2017
Nov;44(4):547-555. doi: 10.1016/j.ucl.2017.07.003.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Kato M, Kimura K, Hirakawa A, Kobayashi Y, Ishida R, Kamihira O,
Majima T, Funahashi Y, Sassa N, Matsukawa Y, Hattori R, Gotoh M,
Tsuzuki T.
Prognostic parameter for high risk prostate
cancer patients at initial presentation.
Prostate. 2017
Nov 2. doi: 10.1002/pros.23438. [Epub ahead of print]
Source
| Full
text |
Similar
articles
|
|
|
PREDIAGNOSTIC
RISK ASSESSMENT WITH PROSTATE MRI AND MRI-TARGETED BIOPSY
|
|
.
|
Bjurlin MA, Taneja SS.
Prediagnostic Risk Assessment with
Prostate MRI and MRI-Targeted Biopsy.
Urol Clin North
Am. 2017 Nov;44(4):535-546. doi: 10.1016/j.ucl.2017.07.012.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Dell'Oglio P, Stabile A, Dias BH, Gandaglia G, Mazzone E, Fossati
N, Cucchiara V, Zaffuto E, Mirone V, Suardi N, Mottrie A, Montorsi
F, Briganti A.
Impact of multiparametric MRI and
MRI-targeted biopsy on pre-therapeutic risk assessment in prostate
cancer patients candidate for radical prostatectomy.
World
J Urol. 2018 Jun 9. doi: 10.1007/s00345-018-2360-1. [Epub ahead of
print]
Source
| Full
text |
Similar
articles
|
|
|
INSIGNIFICANT
DISEASE
|
|
.
|
D'Amico
AV, Chen MH, Roehl KA, Catalona WJ.
Identifying
patients at risk for significant versus clinically insignificant
postoperative prostate-specific antigen failure.
J
Clin Oncol. 2005 Aug 1;23(22):4975-9.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Epstein
JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert
R, Carter HB.
Nonpalpable
stage T1c prostate cancer: prediction of insignificant disease
using free/total prostate specific antigen levels and needle
biopsy findings.
J
Urol. 1998 Dec;160(6 Pt 2):2407-11.
Source
|
Full
text |
Similar
articles
|
|
|
|
Frankcombe DE, Li J, Cohen RJ.
Redefining the Concept of
Clinically Insignificant Prostate Cancer.
Urology. 2019
Nov 9. doi: 10.1016/j.urology.2019.10.019. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
.
|
Hong
SK, Vertosick E, Sjoberg DD, Scardino PT, Eastham JA.
Insignificant
disease among men with intermediate-risk prostate cancer.
World
J Urol. 2014 Dec;32(6):1417-21. doi: 10.1007/s00345-014-1413-3.
Epub 2014 Sep 27.
Source
|
Full
text |
Similar
articles
|
|
|
DEFINING
CLINICALLY SIGNIFICANT PCa ON THE BASIS OF PATHOLOGICAL FINDINGS
|
|
.
|
Matoso A, Epstein JI.
Defining clinically significant
prostate cancer on the basis of pathological findings.
Histopathology. 2019 Jan;74(1):135-145. doi:
10.1111/his.13712.
Source
| Full
text |
Similar
articles
|
|
|
PSA
VELOCITY AND CLASSIFICATION
|
|
.
|
Orsted
DD, Bojesen SE, Kamstrup PR, Nordestgaard BG.
Long-term
Prostate-specific Antigen Velocity in Improved Classification of
Prostate Cancer Risk and Mortality.
Eur
Urol. 2013 Feb 4. doi:pii: S0302-2838(13)00097-3.
10.1016/j.eururo.2013.01.028. [Epub ahead of print]
Source
| Full
text |
Similar
articles
|
|
|
RISK
FACTORS: IMPACT DEPENDS ON RISK GROUP
|
|
|
|
POSITIVE
SURGICAL MARGINS
|
|
.
|
Alkhateeb
S, Alibhai S, Fleshner N, Finelli A, Jewett M, Zlotta A, Nesbitt
M, Lockwood G, Trachtenberg J.
Impact
of positive surgical margins after radical prostatectomy differs
by disease risk group.
J
Urol. 2010 Jan;183(1):145-50. doi: 10.1016/j.juro.2009.08.132.
Epub 2009 Nov 13.
Source
|
Full
text |
Similar
articles
|
|
|
RISK
GROUPS BY PERCENT OF POSITIVE CORES
|
|
.
|
Abdel-Rahman O.
Dissecting the heterogeneity of localized
prostate cancer risk groups through integration of percent of
positive cores.
Future Oncol. 2018 May 10. doi:
10.2217/fon-2017-0596. [Epub ahead of print]
Source
| Full
text |
Similar
articles
|
|
|
COMPARISON
OF PRETREATMENT RISK STRATIFICATION TOOLS
|
|
|
Herlemann A.
Pretreatment Risk Stratification Tools for
Prostate Cancer-Moving from Good to Better, Toward the Best.
Eur Urol. 2019 Nov 3. doi: 10.1016/j.eururo.2019.10.016.
[Epub ahead of print]
Source
.
Similar
articles
Comment
on: Zelic R, et
al, Predicting
Prostate Cancer Death with Different Pretreatment Risk
Stratification Tools: A Head-to-head Comparison in a Nationwide
Cohort Study. Eur Urol. 2019 Oct 9. doi:
10.1016/j.eururo.2019.09.027. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
|
Zelic R, Garmo H, Zugna D, Stattin P, Richiardi L, Akre O,
Pettersson A.
Predicting Prostate Cancer Death with
Different Pretreatment Risk Stratification Tools: A Head-to-head
Comparison in a Nationwide Cohort Study.
Eur Urol. 2019
Oct 9. doi: 10.1016/j.eururo.2019.09.027. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
|
|
|
|
